OPEN ACCESS Freely available online

Lupus: Open Access

Perspective

Clinical Trial Evidence on Stem Cell Therapy for Severe Lupus

Nicholas Carl*

Department of Plastic and Reconstructive Surgery, University of Seville, Seville, Spain

DESCRIPTION

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by widespread inflammation and tissue damage affecting multiple organ systems, including the skin, joints, kidneys, and central nervous system. For patients with severe or refractory lupus, conventional therapies such as corticosteroids, antimalarials, and immunosuppressants often provide limited benefit and come with significant side effects. In recent years, stem cell therapy has emerged as a promising alternative for treating severe lupus. This article provides an in-depth review of the clinical trial evidence supporting the use of stem cell therapy in severe lupus, discussing the mechanisms, outcomes, challenges, and future directions of this innovative treatment approach.

Stem cell therapy involves the use of stem cells, which are undifferentiated cells capable of developing into various cell types, to repair or replace damaged tissues and modulate the immune system. Hematopoietic Stem Cell Transplantation (HSCT) approach involves the infusion of hematopoietic stem cells, typically derived from the patient's own bone marrow or a donor, following a regimen of high-dose immunosuppressive therapy. The goal is to "reset" the immune system by eliminating autoreactive immune cells and replacing them with new, healthy immune cells derived from the transplanted stem cells. Mesenchymal stem cells, derived from sources such as bone marrow, adipose tissue, or umbilical cord, have potent immunomodulatory and anti-inflammatory properties. Mesenchymal Stem Cell (MSC) therapy aims to modulate the immune response in lupus patients by reducing inflammation, promoting tissue repair, and preventing further immune-mediated damage.

HSCT has been studied extensively in patients with severe, refractory lupus, with several clinical trials providing evidence of its efficacy and safety. The first reports of HSCT in lupus appeared in the late 1990s, with case studies and small clinical trials demonstrating promising results. Subsequent small-scale studies reported similar outcomes, with many patients experiencing significant improvement in disease activity and a reduction in the need for immunosuppressive medications. The study also highlighted the potential risks of HSCT, including Treatment-Related Mortality (TRM) and infections, emphasizing the need for careful patient selection and supportive care. The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, although primarily focused on systemic sclerosis, included a subset of lupus patients. The trial further demonstrated the benefits of HSCT in autoimmune diseases, showing sustained remission in many patients, though with significant associated risks.

MSC therapy represents a less intensive alternative to HSCT, with a focus on modulating the immune response rather than completely resetting it. Several clinical trials have investigated the efficacy of MSC therapy in lupus, particularly in patients with lupus nephritis, a severe manifestation of the disease. The first clinical trials of MSC therapy in lupus were conducted in China, with encouraging results. Comparative studies have sought to evaluate the effectiveness of MSC therapy against conventional lupus treatments. A 2015 study compared the outcomes of lupus patients receiving MSC therapy with those on standard immunosuppressive regimens. The MSC group showed better overall response rates and fewer relapses over a 2-year follow-up period. However, the study also noted that MSC therapy did not completely eliminate the need for traditional immunosuppressants in all cases, suggesting that MSCs may be most effective as part of a combination therapy approach. Stem cell therapy is a highly specialized and resource-intensive treatment, which limits its availability to patients in many parts of the world. Additionally, the cost of the procedure can be prohibitive, making it inaccessible to many patients without significant financial support or insurance coverage.

CONCLUSION

Stem cell therapy represents a novel and potentially transformative approach to the treatment of severe lupus, offering hope to patients who have not responded to conventional therapies. Clinical trial evidence supports the efficacy of both HSCT and MSC therapy in inducing remission and reducing disease activity in lupus patients. However, challenges such as treatment-related risks, variable response rates,

Correspondence to: Nicholas Carl, Department of Plastic and Reconstructive Surgery, University of Seville, Seville, Spain, E-mail: nicholasc@gmail.es

Received: 02-Aug-2024, Manuscript No. LOA-24-33723; **Editor assigned:** 05-Aug-2024, PreQC No. LOA-24-33723 (PQ); **Reviewed:** 19-Aug-2024, QC No. LOA-24-33723; **Revised:** 26-Aug-2024, Manuscript No. LOA-24-33723 (R); **Published:** 02-Sep-2024, DOI: 10.35248/2684-1630.24.9.307

Citation: Carl N (2024). Clinical Trial Evidence on Stem Cell Therapy for Severe Lupus. Lupus: Open Access. 9.307

and accessibility issues must be addressed to fully realize the potential of this innovative treatment. Ongoing research and clinical trials will continue to refine and optimize stem cell therapies, with the ultimate goal of providing safe, effective, and accessible treatments for all lupus patients.